New hope for tough blood cancer: experimental drug targets resistant MDS
NCT ID NCT07591168
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BL-M11D1 in 92 adults with a type of blood cancer called myelodysplastic syndromes (MDS) that has returned or not improved with standard treatments. The goal is to find the best dose and see if the drug is safe and can shrink or eliminate cancer cells. Participants will receive the drug by injection and be closely monitored for side effects and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that mimics the body's oxygen sensor may free MDS patients from frequent blood transfusions
- Drug combo aims to break anemia cycle in MDS patients
- Gene mapping of childhood blood cancers could unlock personalized treatments
- Epigenetic drugs aim to stop cancer return after transplant in kids
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
- Can a website ease the emotional toll of stem cell transplants?